Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2019

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
This study is a 12‐week double‐blind, vehicle‐controlled treatment study in which subjects will be randomized to receive tapinarof cream, 1% or vehicle cream once daily for 12 weeks. At the end of the 12‐week study treatment, qualified subjects completing the study will have the option to enter a separate open‐label, long‐term safety and efficacy study for an additional 40 weeks of treatment with tapinarof cream, 1%. Subjects who do not enroll in the open‐label long‐term study will complete a follow‐up visit approximately 4 weeks after end of treatment in this study (at Week 16).
Epistemonikos ID: 0216640a867e5ee8ba82ad96c80286d6163ec146
First added on: May 22, 2024